AbbVie (ABBV) Gains from Investment Securities (2016 - 2026)

AbbVie (ABBV) has reported Gains from Investment Securities for 11 consecutive years, with $2.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 57.25% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $7.4 billion (up 59.08% YoY), while the FY2025 annual figure was $6.5 billion, up 72.24% from the prior year.
• Gains from Investment Securities rose to $2.4 billion in Q1 2026 per ABBV's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $2.8 billion in Q2 2025 and bottomed at -$748.0 million in Q1 2022.
• Historically, Gains from Investment Securities has averaged $1.2 billion across 5 years, with a median of $1.5 billion in 2024.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities plunged 318.37% — and 2024, when it soared 16850.0%.
• AbbVie's Gains from Investment Securities stood at $2.1 billion in 2022, then decreased by 19.77% to $1.7 billion in 2023, then slumped by 83.55% to $279.0 million in 2024, then soared by 403.94% to $1.4 billion in 2025, then soared by 69.77% to $2.4 billion in 2026.
• Business Quant data shows ABBV's Gains from Investment Securities at $2.4 billion in Q1 2026, $1.4 billion in Q4 2025, and $776.0 million in Q3 2025.